Psaltis, Dimitrios http://orcid.org/0000-0003-1035-3240
Settas, Loukas
Georgiadis, Athanasios http://orcid.org/0000-0002-9561-6355
Koukli, Eftichia
Bounas, Andreas
Livieratos, Achilleas http://orcid.org/0000-0003-1444-1408
Petrikkou, Evangelia
Kalogiannaki, Heleni
Repa, Argyro http://orcid.org/0000-0002-1044-2449
Vassilopoulos, Dimitrios http://orcid.org/0000-0003-2288-3863
Sidiropoulos, Prodromos http://orcid.org/0000-0001-9607-0326
Funding for this research was provided by:
MSD Greece
Article History
Received: 14 November 2021
Accepted: 15 December 2021
First Online: 29 January 2022
Declarations
:
: Dr Dimitrios Vassilopoulos has received honoraria from Abbvie, Janssen, MSD, Novartis, Pfizer, Roche, and UCB. Dr Prodromos Sidiropoulos has received honoraria from AbbVie, Amgen, MSD, Novartis, Pfizer, Roche, and UCB. Dr Evangelia Petrikkou and Dr Achilleas Livieratos are employees of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, who may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. For the remaining authors none were declared.
: The study was designed and conducted in accordance with the guidelines for Good Pharmacoepidemiology Practice of the International Society for Pharmacoepidemiology, the ethical principles laid down in the Declaration of Helsinki, and all applicable local rules and regulations. The study was approved by the competent Institutional Review Boards of all participating hospital sites. Participation of private practice investigators was approved by the Institutional Review Board of a participating hospital located in the same geographic region as the Private Practice.
: All persons gave their informed consent prior to their inclusion in the study. All participants provided consent for publication of the material collected in the context of this study in a non-identifiable manner.